Premixed Injectable MTA for Pulpotomy of Primary Teeth
Not Applicable
- Conditions
- Health Condition 1: K040- Pulpitis
- Registration Number
- CTRI/2023/07/055519
- Lead Sponsor
- AISWARYA U S
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Children with bilateral indication for pulpotomy without signs and symptoms of irreversible pulpal damage
Exclusion Criteria
Children with irreversible pulpal damage, sinus or fistula and children with systemic diseases
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Injecatble form of MTA can be used as a Pulpotomy Medicament in Primary teeth. Clinical and radiographic assessment will be done.Timepoint: Over a period of 6 months and one year
- Secondary Outcome Measures
Name Time Method Clinical & radiographic outcome of the pulpotomy with premixed injectable MTA will be assessed over a follow up periodTimepoint: 12 months